Cancers · 2023 · 20 citations · 33 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint ModulationImmunotherapy For Breast CancerImmunotherapy For Solid TumorsCheckpoint Inhibitor CombinationsCtla-4 InhibitionImmune Checkpoint Blockade CombinationsImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor TherapyIntratumoral AdministrationTriple-negative Breast Cancer ImmunotherapyTriple-negative Breast Cancer Therapy
Triple-negative breast carcinoma (TNBC) is one of the most aggressive types of solid-organ cancers. While immune checkpoint blockade (ICB) therapy has significantly improved outcomes in certain types of solid-organ cancers, patients with immunologically cold TNBC are afforded only a modest gain in survival by the addition of ICB to systemic chemotherapy. Thus, it is urgently needed to develop novel effective therapeutic approaches for TNBC. Utilizing the 4T1 murine model of TNBC, we developed a novel combination immunotherapeutic regimen consisting of intratumoral delivery of high-mobility group nucleosome binding protein 1 (HMGN1), TLR2/6 ligand fibroblast-stimulating lipopeptide (FSL-1), TLR7/8 agonist (R848/resiquimod), and CTLA-4 blockade. We also investigated the effect of adding SX682, a small-molecule inhibitor of CXCR1/2 known to reduce MDSC trafficking to tumor microenvironment, to our therapeutic approach. 4T1-bearing mice responded with significant tumor regression and tumor elimination to our therapeutic combination regimen. Mice with complete tumor regressions did not recur and became long-term survivors. Treatment with HMGN1, FSL-1, R848, and anti-CTLA4 antibody increased the number of infiltrating CD4+ and CD8+ effector/memory T cells in both tumors and draining lymph nodes and triggered the generation of 4T1-specific cytotoxic T lymphocytes (CTLs) in the draining lymph nodes. Thus, we developed a potentially curative immunotherapeutic regimen consisting of HMGN1, FSL-1, R848, plus a checkpoint inhibitor for TNBC, which does not rely on the administration of chemotherapy, radiation, or exogenous tumor-associated antigen(s).
33
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vétizou, Jonathan M. Pitt, Romain Daillère et al. · Science · 2015 · 3.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen, Diana Miao, Bastian Schilling et al. · Science · 2015 · 3K citations · Full text
Medicine, Cancer Biology, Oncology +17
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Răzvan Cristescu, Robin Mogg, Mark Ayers et al. · Science · 2018 · 2.3K citations
Medicine, Immunology, Oncology +17